Literature DB >> 14689749

Initial experience with ovarian vein embolization for the treatment of chronic pelvic pain syndrome.

Gil Nissim Bachar1, Alexander Belenky, Franklin Greif, Eli Atar, Yigal Gat, Maxim Itkin, Anthony Verstanding.   

Abstract

BACKGROUND: Ovarian vein embolization was recently suggested as the preferred treatment for chronic pelvic pain syndrome.
OBJECTIVE: To evaluate the technical feasibility, complications and early clinical and radiographic results of ovarian vein embolization in women with pelvic pain syndrome.
METHODS: Percutaneous transcatheter ovarian vein embolization with coils was performed in six patients aged 27-53 years who presented with pelvic pain syndrome. All had lower abdominal pain, and pelvic varicosities were found on Doppler ultrasound and retrograde ovarian vein venography. Embolization was done unilaterally in three patients (on the left side) and bilaterally in three. Mean follow-up by telephone questionnaire was 7.3 months.
RESULTS: The procedure was technically successful in all patients. Two patients reported partial relief of symptoms (33.3%) and three had complete relief (50%), for a total of 5 patients (83.3%) with some measure of improvement. There were no complications following the procedure.
CONCLUSIONS: Percutaneous transcatheter ovarian vein embolization seems to be safe and feasible for the treatment of pelvic pain syndrome. The procedure is performed on an outpatient basis and is well tolerated by patients.

Entities:  

Mesh:

Year:  2003        PMID: 14689749

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  2 in total

1.  Predicting pelvic congestion syndrome: Concomitant pelvic pain diagnoses do not affect venography or embolization outcomes.

Authors:  Jared Macher; Akshaar Brahmbhatt; Anisha Shetty; Komal Chughtai; Timothy Baran; Nana Ohene Baah; Vikram Dogra
Journal:  J Clin Imaging Sci       Date:  2021-11-15

Review 2.  Female Pelvic Vein Embolization: Indications, Techniques, and Outcomes.

Authors:  Anthony James Lopez
Journal:  Cardiovasc Intervent Radiol       Date:  2015-03-25       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.